HOME >> MEDICINE >> NEWS
Once-a-month injectable medication helps treat alcohol dependence

ng days and 190 mg. of naltrexone resulted in a 17 percent decrease. Sex and pretreatment abstinence each showed significant interaction with the medication group on treatment outcome, with men and those with lead-in abstinence both exhibiting greater treatment effects. Discontinuation due to adverse events (e.g. nausea, headache, fatigue) occurred in 14.1 percent in the 380-mg. and 6.7 percent in the 190-mg. group and 6.7 percent in the placebo group. Overall, rate and time to treatment discontinuation were similar among treatment groups.

"In summary, the results from this trial, with one of the largest samples ever treated with a medication for alcohol dependence, indicate that long-acting injectable naltrexone is well tolerated and is associated with a significant reduction in heavy drinking in a population of actively drinking patients. The long-acting formulation has the potential to improve intervention strategies for alcohol dependence by providing a predictable pharmacological foundation for treatment. In addition to their utility for alcohol dependence, long-acting formulations may prove to be an important treatment strategy for a variety of addictive disorders," the authors write.


'"/>

Contact: Stephanie Crayton
919-966-2860
JAMA and Archives Journals
5-Apr-2005


Page: 1 2

Related medicine news :

1. Once-a-month naltrexone successfully used to treat alcohol dependence
2. New study shows patients more willing to consider self-injectable HIV therapy than many physicians anticipate
3. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
4. Adding medication improves recovery for elderly with depression, says Pitt School of Medicine study
5. Heart failure medication does not improve survival, compared to more widely used medication
6. Commonly used pain medications do not prevent Alzheimers disease
7. Standard long-acting insulin as good as newer medications
8. MS patients not receiving medications to slow disease progression, research shows
9. Study sheds light on medication treatment options for bipolar disorder
10. Landmark schizophrenia treatment study reveals that medication alone is not always effective
11. Cost control measures limit patient and physician choice in psychotropic medications

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/31/2020)... ... August 31, 2020 , ... Bonde Innovations, LLC, a venture-backed ... heart failure, today announced that the company has been awarded a Phase 1 ... National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH). ...
(Date:8/28/2020)... ... August 28, 2020 , ... WHAT , Hespiro™ is ... with respiratory conditions, including COVID-19, while reducing the need for scarce mechanical ventilators. ... exhaled gas and scrubs it free of carbon dioxide in a completely closed ...
(Date:8/28/2020)... ... ... Integrated Viral Protection (IVP Air) today announced that the True North Classical ... Indoor Air Protection System that is the first system designed and proven to catch ... the filtration system on September 8th. , The IVP Air S1 model is ...
(Date:8/27/2020)... ... 2020 , ... Walk-in Dermatology’s SK-IN Medical Aesthetics Center announced ... York location. , Loren received her New York esthetic license in 2009 ... peels, microdermabrasion, Hydrafacial MD, dermaplaning, facial lymphatic, and various laser procedures. Loren is ...
(Date:8/26/2020)... ... 2020 , ... Smile Brands Inc. CEO, Steven C. Bilt, ... a session entitled, “A CEO Guide for Delivering and Measuring Inclusion Success”. The ... together the world’s leading diversity and inclusion executives, HR consultants, and D&I activists ...
Breaking Medicine News(10 mins):
(Date:8/26/2020)... ... August 26, 2020 , ... Hero Life Sciences announced today that ... 3 ply surgical disposable face masks and N95 respirators in its manufacturing plant located ... challenge that most Americans are facing in trying to find quality disposable face masks ...
(Date:8/26/2020)... ... 26, 2020 , ... NucleusHealth, LLC, a provider of market ... and Chief Executive Officer effective immediately. Dr. Vishal Verma, the previous CEO, will ... , Mr. Hooton, a seasoned business executive, joined the company in February ...
(Date:8/26/2020)... SAN DIEGO (PRWEB) , ... August 25, 2020 ... ... opening of its brand new Stem Cell Treatment Center to give ... stress free environment. With this announcement, ProgenCell establishes its leadership in the field ...
Breaking Medicine Technology:
Cached News: